Combined analyses and extended follow-up of two randomized controlled homocysteine-lowering B-vitamin trials: Original Article

Journal of Internal Medicine

Volumn 268, Issue 4, 2010, Pages 367-382

  Ebbing, M ^a   Bonaa K H ^b,c   Arnesen, E ^c   Ueland, P M ^d   Nordrehaug, J E ^a,d   Rasmussen, K ^b,c   Njolstad I ^c   Nilsen, D W ^d,e   Refsum, H ^f,g   Tverdal, A ^h   Vollset, S E ^d,h   Schirmer, H ^b,c   Bleie, Ø ^a   Steigen, T ^b,c   Midttun, Ø ⁱ   Fredriksen, A ⁱ   Pedersen, E R ^d   Nyga rd O ^a,d  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e STAVANGER UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

ⁱ BEVITAL AS   (Norway)

Author keywords

cardiovascular disease; folic acid; homocysteine; randomized controlled trial; vitamin B12

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PLACEBO; PYRIDOXINE; VITAMIN B GROUP;

ACUTE HEART INFARCTION; ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART DEATH; HUMAN; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TREATMENT DURATION;

CAPSULES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE; TREATMENT OUTCOME; VITAMIN B 12; VITAMIN B 6; VITAMIN B COMPLEX;

EID: 77956305806     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02259.x     Document Type: Article

References (47)

1. Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998 49 : 31 62.
2. Arnesen E, Refsum H, Bønaa KH, Ueland PM, Førde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995 24 : 704 709.
3. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997 337 : 230 236.
4. Nygård O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin Nutr 1998 67 : 263 270.
5. Selhub J, Jacques PF, Rosenberg IH et al. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med 1999 131 : 331 339.
6. Robinson K, Mayer EL, Miller DP et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995 92 : 2825 2830.
7. Robinson K, Arheart K, Refsum H et al. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 1998 97 : 437 443.
8. Rimm EB, Willett WC, Hu FB et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998 279 : 359 364.
9. Clarke R, Armitage J, Lewington S, Collins R. Homocysteine-lowering trials for prevention of vascular disease: protocol for a collaborative meta-analysis. Clin Chem Lab Med 2007 45 : 1575 1581.
10. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995 274 : 1049 1057.
11. Tice JA, Ross E, Coxson PG et al. Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. JAMA 2001 286 : 936 943.
12. Centers for Disease Control and Prevention. Trends in wheat-flour fortification with folic acid and iron - worldwide, 2004 and 2007. MMWR Morb Mortal Wkly Rep 2008 57 : 8 10.
13. Lonn E, Yusuf S, Arnold MJ et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006 354 : 1567 1577.
14. Albert CM, Cook NR, Gaziano JM et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008 299 : 2027 2036.
15. Toole JF, Malinow MR, Chambless LE et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004 291 : 565 575.
16. Baker F, Picton D, Blackwood S, Hunt J, Erskine M, Dyas M. Blinded comparison of folic acid and placebo in patients with ichemic heart disease: an outcome trial. Circulation 2002 106 (suppl 2 741.
17. Bønaa KH, Njølstad I, Ueland PM et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006 354 : 1578 1588.
18. Ebbing M, Bleie Ø, Ueland PM et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 2008 300 : 795 804.
19. Armitage J. SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine): randomized comparison of folic acid 2 mg plus vitamin B12 1 mg daily versus placebo for 7 years in 12,064 myocardial infarction survivors. Circulation 2008 118 : 2310.
20. Jamison RL, Hartigan P, Kaufman JS et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007 298 : 1163 1170.
21. Hogan M. Lowering homocysteine levels with folic acid of no benefit in kidney transplant recipients. Nephrology Times 2009 2 : 16 8.
22. Marti-Carvajal AJ, Sola I, Lathyris D, Salanti G. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2009 : CD006612.
23. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C >T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002 288 : 2023 2031.
24. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002 325 : 1202.
25. Kelleher BP, Broin SD. Microbiological assay for vitamin B12 performed in 96-well microtitre plates. J Clin Pathol 1991 44 : 592 595.
26. O'Broin S, Kelleher B. Microbiological assay on microtitre plates of folate in serum and red cells. J Clin Pathol 1992 45 : 344 347.
27. Windelberg A, Arseth O, Kvalheim G, Ueland PM. Automated assay for the determination of methylmalonic acid, total homocysteine, and related amino acids in human serum or plasma by means of methylchloroformate derivatization and gas chromatography-mass spectrometry. Clin Chem 2005 51 : 2103 2109.
28. Midttun Ø, Hustad S, Ueland PM. Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2009 23 : 1371 1379.
29. Meyer K, Fredriksen Å, Ueland PM. MALDI-TOF MS genotyping of polymorphisms related to 1-carbon metabolism using common and mass-modified terminators. Clin Chem 2009 55 : 139 149.
30. Statistics Norway. Causes of deaths, 2007. Statistics Norway (Statistisk sentralbyrå ) 2009 (cited 2010 January 18); Available from: http://www.ssb.no/dodsarsak-en/.
31. Cleves M, Gutierrez R, Gould W, Marchenko Y. The Cox model: Diagnostics. In : An Introduction to Survival Analysis Using Stata. College Station : Stata Press 2008 197 202.
32. Refsum H, Smith AD, Ueland PM et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004 50 : 3 32.
33. Anderson JL, Muhlestein JB, Horne BD et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000 102 : 1227 1232.
34. Omland T, Samuelsson A, Hartford M et al. Serum homocysteine concentration as an indicator of survival in patients with acute coronary syndromes. Arch Intern Med 2000 160 : 1834 1840.
35. Stubbs PJ, Al-Obaidi MK, Conroy RM, Collinson PO, Graham IM, Noble IM. Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. Circulation 2000 102 : 605 610.
36. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 2008 83 : 1203 1212.
37. Van Guelpen B, Hultdin J, Johansson I et al. Plasma folate and total homocysteine levels are associated with the risk of myocardial infarction, independently of each other and of renal function. J Intern Med 2009 266 : 182 195.
38. Lewis SJ, Ebrahim S, Davey Smith G. Meta-analysis of MTHFR 677C->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ 2005 331 : 1053.
39. Zee RY, Mora S, Cheng S et al. Homocysteine, 5,10- methylenetetrahydrofolate reductase 677C>T polymorphism, nutrient intake, and incident cardiovascular disease in 24,968 initially healthy women. Clin Chem 2007 53 : 845 851.
40. Fredriksen Å, Meyer K, Ueland PM, Vollset SE, Grotmol T, Schneede J. Large-scale population-based metabolic phenotyping of thirteen genetic polymorphisms related to one-carbon metabolism. Hum Mutat 2007 28 : 856 865.
41. Joseph J, Handy DE, Loscalzo J. Quo Vadis: Whither Homocysteine Research? Cardiovasc Toxicol 2009 9 : 53 63.
42. Refsum H, Nurk E, Smith AD et al. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr 2006 136 : 1731S 40S.
43. Kielstein JT, Salpeter SR, Buckley NS, Cooke JP, Fliser D. Two Cardiovascular Risk Factors in One? Homocysteine and Its Relation to Glomerular Filtration Rate. A Meta-Analysis of 41 Studies with 27,000 Participants. Kidney Blood Press Res 2008 31 : 259 267.
44. Schroecksnadel K, Frick B, Winkler C, Fuchs D. Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol 2006 4 : 205 213.
45. Maron BA, Loscalzo J. The treatment of hyperhomocysteinemia. Annu Rev Med 2009 60 : 39 54.
46. Ebbing M, Bønaa KH, Nygård O et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 2009 302 : 2119 2126.
47. Dierkes J, Weikert C, Klipstein-Grobusch K et al. Plasma pyridoxal-5-phosphate and future risk of myocardial infarction in the European Prospective Investigation into Cancer and Nutrition Potsdam cohort. Am J Clin Nutr 2007 86 : 214 220.